KRAS and cancer: As expected, KRAS-mutant cancer cell lines were more sensitive to a commercially available MEK inhibitor, trametinib, than were KRAS wild-type cancer cell lines based on screening data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) (Fig. 4A, Supplementary Table 8).